Skip to main content
Dana-Farber
  • person
  • dana-farber.org
  • Search
  • Featured Specialties
    • Breast Oncology
    • Gastrointestinal Oncology
    • Genitourinary Oncology
    • Gynecologic Oncology
    • Hematologic Oncology
    • Pediatric Oncology
  • Find a Physician
  • Find a Clinical Trial
  • Refer a Patient
  • Contact Us

Jennifer R. Brown, MD, PhD

Medical Oncology

Jennifer R. Brown, MD, PhD

Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction. She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize. She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at DFCI. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL.

 

View Full Profile


Related Videos

Jennifer Brown, MD, PhD reviews Phase 2 Amplify trial Video

Jennifer Brown, MD, PhD reviews Phase 2 Amplify trial

Dana-Farber Cancer Institute's Jennifer Brown, MD, PhD, shared results at #ASH24 from the Phase 3 AMPLIFY trial: novel oral regimens show promise for CLL with durable, deep responses.

Jennifer Brown, MD, PhD, Discusses ALPINE Trial Video

Jennifer Brown, MD, PhD, Discusses ALPINE Trial

Jennifer Brown, MD, PhD, Dana-Farber, presented updated results of the Phase 3 randomized ALPINE trial at ASH23. The updated analysis shows in CLL/SLL treatment, zanubrutinib maintains superior progression-free survival over ibrutinib.

Zanubrutinib improves progression-free survival in relapsed CLL Video

Zanubrutinib improves progression-free survival in relapsed CLL

Dana-Farber's Jennifer Brown, MD, PhD, says the phase 3 ALPINE randomized trial shows the drug zanubrutinib is superior to ibrutinib in relapsed/refractory chronic lymphocytic leukemia and should be considered a new standard of care.

Next Questions: Chronic Lymphocytic Leukemia Video

Next Questions: Chronic Lymphocytic Leukemia

Jennifer Brown, MD, PhD, shares about multiple treatments and drug therapies and how long patients can remain on them while determining the best outcomes.

Connect with us

Facebook_DanaFarber_Blue_icon X_DanaFarber_Blue_icon Instagram_DanaFarber_Blue_icon Youtube_DanaFarber_Blue_icon LinkedIn_DanaFarber_Blue_icon
  • About Us
  • Research
  • Medical Oncology Spotlight
  • Find a Clinical Trial
  • Find a Physician
  • Refer a Patient
  • Clinical Resources
  • Dana-Farber
Powered by BroadcastMedBROADCASTMED